Nowadays, the anti-CTLA4 ipilimumab (Bristol-Meyers Squibb), the anti-PD-1 nivolumab (Bristol-Meyers Squibb), pembrolizumab (Merck), and the anti-PD-L1 atezolizumab (Roche) are approved for the treatment of numerous cancers (e.g., melanoma, NSCLC, RCC). The gene discussed is CD274; the disease is melanoma.